1VAN CUTSEM E, HALLER D, OHTSU A. The role of chemotheraphy in the current treatment of gastric cancer [J], Cancer, 2002,5(Suppl) : 17-22.
2EARLE C C, MARON J A. Adjuvant chemotheraphy after curative resection for gastric cancer in non Asian pations: revisiting a meta-analyais of randomized trials[J]. Eur J Can cer, 1999,35:1059-1064.
3PANZINI I, GIANNI L, FATTORI P P, et al. Adjuvant chemotherapy in gastric canaer: a meta-analysis of randomized trials and a comparison with previous recta-analyses[J]. Tumori, 2002,88:21-27.
4HUNDAHL S A, PHILLIOS J L, MENCK H R, et al. The National Cancer Data Base report on poor survival of U. S. gastris carcinoma pations treated with gastreetomy[J]. Cancer, 2000,88 : 921-932.
1De Gramont A,Figer A,Seymour M,et al.Leucovorin and fiuorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer [ J ].J clin 0ncol,2000,18 ( 16 ) :2938 - 2947.
6Znone, Tsngcme S. Epidemiology of gastric cancer in Ja- pan. MedJ, 2005, 81: 419.
7Komatsu Y, Takahashi Y, Kimura Y. Randomized phase II trial of first - line treatment with tailored ifinotecan and S - 1 therapy versus S - 1 monotherapy for advanced or recurrent gastric carcinoma (JFMC31 - 0301 ) . Anficancer Drugs, 2011,22(6) :576 -583.
8Fujitani K, Hasegawa H, Hirao M, et al. Feasibility study of triplet combination chemotherapy d paclltaxel, cisplatin and S - 1 for advanced gastric cancer. Antlcancer Res,2011,31 (9) :3 085 -3 091.
9Eisenhauer EA,Therasse P,Bogaerts J,et al. New zesponse evaluation criteria in solid tmnours: revised RECIST guide- line ( version 1.1 ). European Journal of Cancer,2009,45: 228 - 249.
10A1 - Batran SE, Harunann iT, Probst S, et al. Phase m Trial in Metastatic gastroesophageal adenocarcinoma with fluorouracil, leucororin plus either oxaliplatin or cisplatin:.A study of the Arbeitsgemeinschaft Intemistische Onkoli- gie. Clin 0ncol,2008,26(9) :1 435 -1 442.
